<DOC>
	<DOCNO>NCT02693236</DOCNO>
	<brief_summary>The aim Phase I/II study evaluate safety efficacy dendritic cell ( DC ) combine cytokine-induced killer ( CIK ) cell patient advance esophagus cancer . Experimental recombinant adenovirus cod mRNA include MUC1 Survivin transfected DC , use DC-based immunotherapy . Based result previously perform preclinical study DC vaccine combine CIK cell , researcher plan perform clinical trial .</brief_summary>
	<brief_title>DC Vaccine Combined With CIK Cells Patients With Esophagus Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histopathologically confirm diagnosis esophagus cancer Age &gt; 18 year time consent Received standardize treatment SmallCell Lung Cancer Interval last standardized treatment DC/CIK treatment â‰¥ 4weeks KPS ( Karnofsky performance scale ) &gt; 60 Patient 's write informed consent No severe viral bacterial infection Predicted survival &gt; 3 month Serious dysfunction vital organ ( heart , liver kidney ) History autoimmune disease Pregnant breastfeed patient Active chronic infectious disease History allergy hypersensitivity study product excipients Currently participate another clinical trial Received chemotherapy , radiotherapy , immune inhibitor ( corticosteroid ) immunotherapy ( vaccine ) prior 4 week Clinically relevant disease infection ( HBV , HCV , HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>